WO2021081110A3 - Peptides and use thereof - Google Patents

Peptides and use thereof Download PDF

Info

Publication number
WO2021081110A3
WO2021081110A3 PCT/US2020/056686 US2020056686W WO2021081110A3 WO 2021081110 A3 WO2021081110 A3 WO 2021081110A3 US 2020056686 W US2020056686 W US 2020056686W WO 2021081110 A3 WO2021081110 A3 WO 2021081110A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
bacterial infections
caused
pharmaceutical compositions
infectious diseases
Prior art date
Application number
PCT/US2020/056686
Other languages
French (fr)
Other versions
WO2021081110A2 (en
Inventor
Jason ROLAND
Andrew Goodrich
Sergio Duron
Deborah Nguyen
Original Assignee
Anexigen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anexigen, Inc. filed Critical Anexigen, Inc.
Publication of WO2021081110A2 publication Critical patent/WO2021081110A2/en
Publication of WO2021081110A3 publication Critical patent/WO2021081110A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Described herein are peptides comprising anti-microbial activity. Such peptides in some embodiments are used as pharmaceutical compositions to treat infectious diseases, such as bacterial infections. In some embodiments, the bacterial infections are caused by multi-drug resistant bacteria.
PCT/US2020/056686 2019-10-22 2020-10-21 Peptides and use thereof WO2021081110A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924629P 2019-10-22 2019-10-22
US62/924,629 2019-10-22

Publications (2)

Publication Number Publication Date
WO2021081110A2 WO2021081110A2 (en) 2021-04-29
WO2021081110A3 true WO2021081110A3 (en) 2021-07-01

Family

ID=75620259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/056686 WO2021081110A2 (en) 2019-10-22 2020-10-21 Peptides and use thereof

Country Status (1)

Country Link
WO (1) WO2021081110A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021081110A2 (en) * 2019-10-22 2021-04-29 Anexigen, Inc. Peptides and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770798B1 (en) * 1997-11-07 2004-08-03 Aventis Cropscience Nucleic acid sequences coding for thanatin and transformed plants containing them
US20140142028A1 (en) * 2009-02-05 2014-05-22 The Regents Of The University Of California Targeted antimicrobial moieties
WO2017004591A2 (en) * 2015-07-02 2017-01-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
WO2021081110A2 (en) * 2019-10-22 2021-04-29 Anexigen, Inc. Peptides and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770798B1 (en) * 1997-11-07 2004-08-03 Aventis Cropscience Nucleic acid sequences coding for thanatin and transformed plants containing them
US20140142028A1 (en) * 2009-02-05 2014-05-22 The Regents Of The University Of California Targeted antimicrobial moieties
WO2017004591A2 (en) * 2015-07-02 2017-01-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
WO2021081110A2 (en) * 2019-10-22 2021-04-29 Anexigen, Inc. Peptides and use thereof

Also Published As

Publication number Publication date
WO2021081110A2 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2022006525A (en) Lysin polypeptides active against gram-negative bacteria.
WO2017017631A3 (en) Antibacterial therapeutics and prophylactics
MX2016015218A (en) Macrocyclic broad spectrum antibiotics.
BRPI0807487A8 (en) USE OF IL-23 ANTAGONISTS FOR THE TREATMENT OF INFECTION
ATE452138T1 (en) ANTIBACTERIAL PEPTIDES AND ANALOGUES THEREOF
MX2015015506A (en) Antimicrobial peptide.
MX2015006340A (en) Macrocyclic broad spectrum antibiotics.
MX2018006190A (en) Macrocyclic broad spectrum antibiotics.
MX2018006199A (en) Macrocyclic broad spectrum antibiotics.
MX2021005421A (en) C11-cyclic substituted 13-membered macrolides and uses thereof.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
MX2021014554A (en) Macrocyclic broad spectrum antibiotics.
WO2019077634A3 (en) Therapeutic compositions of antimicrobial peptides
WO2021004958A3 (en) Compositions comprising bacterial strains
ATE433459T1 (en) DESOXO-NONADEPSIPEPTIDES
WO2018109042A3 (en) Antimicrobial peptides
MX2021005423A (en) C10-alkylene substituted 13-membered macrolides and uses thereof.
MX2016007626A (en) Antimicrobial peptide and uses thereof.
WO2019067498A3 (en) Peptide antibiotic complexes and methods of use thereof
WO2021081110A3 (en) Peptides and use thereof
MX2020012543A (en) Diltiazem for use in the treatment of microbial infections.
AU2018257122A1 (en) Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof
WO2020232471A3 (en) Methods and compositions comprising staphylococcus protein a (spa) variants
AU2018272839A8 (en) Fractionated antimicrobial compositions and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20879246

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20879246

Country of ref document: EP

Kind code of ref document: A2